Author

S. E. Richardson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

A. Garcia-Gimenez· 2 shared B. Huntly· 2 shared N. Sakakini· 2 shared R. Asby· 2 shared S. J. Horton· 2 shared A. Godsinia· 1 shared A. Illendula· 1 shared A. R. Fard· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Garcia-Gimenez

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Mutational synergy with CREBBP loss in lymphomagenesis identified through forward insertional mutagenesis in a new DLBCL mouse model

N. Sakakini, R. Straver, D. Azazi, S. J. Horton, R. Asby, S. E. Richardson, P. Madrigal, E. E. Soilleux, R. J. M. Bashford-Rogers, J. de Ridder, B. J. P. Huntly

bioRxiv · Mar 25, 2024 · PreprintCancer Biology

Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

A. Garcia-Gimenez, J. E. Ditcham, D. M. A. Azazi, E. Meduri, R. Asby, N. Sakakini, C. K. Lopez, N. Narayan, T. Beinortas, J. Bagri, S. Agrawal Singh, G. Giotopoulos, M. P. Murphy, S. J. Horton, B. Huntly, S. E. Richardson

This study identifies CREBBP mutations as a targetable vulnerability in B-ALL, showing that CREBBP inhibition sensitizes these cells to Venetoclax-induced ferroptosis.

bioRxiv · Oct 2, 2023 · PreprintCancer Biology

LGR5 targeting molecules as therapeutic agents for multiple cancer types

H.-C. Chen, N. Mueller, K. Stott, E. Rivers, C. Kapeni, C. M. Sauer, F. Beke, S. Walsh, N. Ashman, L. M. O'Brien, A. R. Fard, A. Godsinia, F. Joud, O. Giger, I. Zlobec, , M. de la Roche

This study develops LGR5-targeting antibodies and therapeutics that effectively kill CRC, HCC, and pre-B ALL cancer cells while sparing normal tissues.

bioRxiv · Sep 1, 2022 · PreprintCell Biology

Cell cycle corruption in a preleukemic ETV6-RUNX1 model exposes RUNX1 addiction as a therapeutic target in acute lymphoblastic leukemia

J. P. Wray, E. M. Deltcheva, C. Boiers, S. E. Richardson, J. B. Chhetri, S. Gagrica, Y. Guo, A. Illendula, J. H. Martens, H. H. Stunnenberg, J. H. Bushweller, R. Nimmo, T. Enver

This study shows that RUNX1 addiction is a therapeutic target in acute lymphoblastic leukemia, as inhibiting RUNX1 activity spares normal hematopoiesis and affects multiple genetic subtypes.

bioRxiv · Dec 22, 2020 · PreprintCancer Biology